Yes, GBM would be an additional $3+ billion to that number. If they can use DCVax to somehow extend their patents, then DCvax becomes essential to Merck.
Thx e8! Also remember that by Keytruda’s patent expiration in 2028, expected sales will be $30B; the ONLY $30B brand on the market!!! Currently, there is no other brand projected to be selling even $20B/annually by 2028!!! I would add: brands NOT CURRENTLY approved;)!